TRAVELLER Study

What is the TRAVELLER Study? 

This is a global, multi-center pre-screening study. The study is designed to detect early signs of cognitive impairment and measure pTau217 biomarker levels in participants who may be in the early stages of, or at risk of developing, Alzheimer’s disease (AD) dementia. This study does not involve any investigational medication. However, patients may be referred to screening for Roche interventional AD clinical trials based on cognitive testing and a blood test detecting plasma levels of a protein called pTau217, a biomarker associated with changes related to Alzheimer's disease. Study duration is expected to be a couple of hours over 1 or 2 days.

What is the purpose of the TRAVELLER Study? 

The purpose of the TRAVELLER study is to identify people who are best suited to participate in one of Roche’s Alzheimer’s disease clinical studies. This study also aims to engage with diverse communities to ensure we include all people living with Alzheimer’s disease, regardless of race, ethnicity, physical or mental ability, religion, and education or income level.

Eligibility 

The participants in this study must be between the ages of 50-90 and willing to participate in a clinical study. Interested participants can contact the Memory and Aging Program Outreach Team at (401) 455-6402 or by sending an email to memory@butler.org to discuss additional eligibility criteria.

Interested participants can contact the Memory and Aging Program Outreach Team at (401) 455-6402 or by sending an email to memory@butler.org to discuss additional eligibility criteria.